RT Journal Article
SR Electronic
T1 UV-C Tower for point-of-care decontamination of filtering facepiece respirators
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20133777
DO 10.1101/2020.06.17.20133777
A1 Badar J. Kayani
A1 Davis T. Weaver
A1 Vishvaan Gopalakrishnan
A1 Eshan S. King
A1 Emily Dolson
A1 Nikhil Krishnan
A1 Julia Pelesko
A1 Michael J. Scott
A1 Masahiro Hitomi
A1 Jennifer L. Cadnum
A1 Daniel F. Li
A1 Curtis J. Donskey
A1 Jacob G. Scott
A1 Ian Charnas
YR 2020
UL http://medrxiv.org/content/early/2020/08/18/2020.06.17.20133777.abstract
AB Filtering facepiece respirators (FFR) are critical for protecting essential personnel and limiting the spread of disease. Due to the current COVID-19 pandemic, FFR supplies are dwindling in many health systems, necessitating re-use of potentially contaminated FFR. Multiple decontamination solutions have been developed to meet this pressing need, including systems designed for bulk decontamination of FFR using vaprous hydrogen peroxide or UV-C radiation. However, the large scale on which these devices operate may not be logistically practical for small or rural health care settings or for ad hoc use at points-of-care. Here, we present the Synchronous UV Decontamination System (SUDS), a novel device for rapidly deployable, point-of-care decontamination using UV-C germicidal irradiation. We designed a compact, easy-to-use device capable of delivering over 2 J· cm−2 of UV-C radiation in one minute. We experimentally tested SUDS’ microbicidal capacity and found that it eliminates near all virus from the surface of tested FFRs, with less efficacy against pathogens embedded in the inner layers of the masks. This short decontamination time should enable care-providers to incorporate decontamination of FFR into a normal donning and doffing routine following patient encounters.Competing Interest StatementIan Charnas and Jacob Scott are listed as inventors on a provisional patent application for this deviceFunding StatementWe would like to extend our special thanks to Miguel Zubizarreta, whose generous and timely gift made this and many other COVID rapid response projects possibleAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patient data was used in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code, data, and technical documents are available at https://github.com/TheoryDivision/SUDS. https://github.com/TheoryDivision/SUDS